{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:44:04Z","timestamp":1786160644607,"version":"build-2736575974"},"reference-count":93,"publisher":"Japan Endocrine Society","issue":"8","funder":[{"name":"Liaoning Provincial Science and Technology Plan Joint Program","award":["2024011925-JH3"],"award-info":[{"award-number":["2024011925-JH3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej26-0050","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:10:33Z","timestamp":1777414233000},"page":"907-922","source":"Crossref","is-referenced-by-count":0,"title":["Soluble tumor necrosis factor receptors in diabetes: risk sensing and receptor-resolved targeting"],"prefix":"10.1507","volume":"73","author":[{"given":"Qi","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Emergency, Central Hospital Affiliated to Shenyang Medical College, Shenyang 110032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Central Hospital Affiliated to Shenyang Medical College, Shenyang 110032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Central Hospital Affiliated to Shenyang Medical College, Shenyang 110032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8676-3903","authenticated-orcid":false,"given":"Tie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Central Hospital Affiliated to Shenyang Medical College, Shenyang 110032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, et al. (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402: 203\u2013234.","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Hoogeveen EK (2022) The epidemiology of diabetic kidney disease. Kidney Dial 2: 433\u2013442.","DOI":"10.3390\/kidneydial2030038"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Mutruc V, Bologa C, \u0218orodoc V, Ceasovschih A, Mor\u0103ra\u0219u BC, et al. (2025) Cardiovascular-kidney-metabolic syndrome: a new paradigm in clinical medicine or going back to basics? J Clin Med 14: 2833.","DOI":"10.3390\/jcm14082833"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Kist M, K\u0151m\u0171ves LG, Goncharov T, Dugger DL, Yu C, et al. (2021) Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. Cell Death Differ 28: 985\u20131000.","DOI":"10.1038\/s41418-020-00629-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Inoue M, Tsuji Y, Ueno R, Miyamoto D, Tanaka K, et al. (2023) Bivalent structure of a TNFR2-selective and agonistic TNF-\u03b1 mutein Fc-fusion protein enhances the expansion activity of regulatory T cells. Sci Rep 13: 13762.","DOI":"10.1038\/s41598-023-40925-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214: 149\u2013160.","DOI":"10.1002\/path.2287"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Bell JH, Herrera AH, Li Y, Walcheck B (2007) Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol 82: 173\u2013176.","DOI":"10.1189\/jlb.0307193"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8 Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, et al. (1998) An essential role for ectodomain shedding in mammalian development. Science 282: 1281\u20131284.","DOI":"10.1126\/science.282.5392.1281"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Annibaldi A, Meier P (2018) Checkpoints in TNF-induced cell death: implications in inflammation and cancer. Trends Mol Med 24: 49\u201365.","DOI":"10.1016\/j.molmed.2017.11.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Zhang N, Liu J, Guo R, Yan L, Yang Y, et al. (2024) Palmitoylation licenses RIPK1 kinase activity and cytotoxicity in the TNF pathway. Mol Cell 84: 4419\u20134435.e10.","DOI":"10.1016\/j.molcel.2024.10.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Song D, Cen Y, Qian Z, Wu XS, Rivera K, et al. (2024) PTPN23-dependent ESCRT machinery functions as a cell death checkpoint. Nat Commun 15: 10364.","DOI":"10.1038\/s41467-024-54749-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Nam YW, Shin JH, Kim S, Hwang CH, Lee CS, et al. (2024) EGFR inhibits TNF-\u03b1-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401. Cell Death Differ 31: 1318\u20131332.","DOI":"10.1038\/s41418-024-01316-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Karathanasis C, Medler J, Fricke F, Smith S, Malkusch S, et al. (2020) Single-molecule imaging reveals the oligomeric state of functional TNF\u03b1-induced plasma membrane TNFR1 clusters in cells. Sci Signal 13: eaax5647.","DOI":"10.1126\/scisignal.aax5647"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Cheng CT, Hsiao JC, Hoffmann A, Tu HL (2024) TNFR1 mediates heterogeneity in single-cell NF-\u03baB activation. iScience 27: 109486.","DOI":"10.1016\/j.isci.2024.109486"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Su Z, Dhusia K, Wu Y (2022) Understanding the functional role of membrane confinements in TNF-mediated signaling by multiscale simulations. Commun Biol 5: 228.","DOI":"10.1038\/s42003-022-03179-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Lim CS, Lee J, Kim JW, Lee JO (2025) Highly ordered clustering of TNF\u03b1 and BAFF ligand-receptor-intracellular adaptor complexes on a lipid membrane. Nat Commun 16: 5551.","DOI":"10.1038\/s41467-025-61271-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Yu X, James S, Felce JH, Kellermayer B, Johnston DA, et al. (2021) TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity. Commun Biol 4: 772.","DOI":"10.1038\/s42003-021-02309-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Zhu Y, Wang L, Li J, Zhao Y, Yu X, et al. (2024) Photoaffinity labeling coupled with proteomics identify PDI-ADAM17 module is targeted by (\u2013)-vinigrol to induce TNFR1 shedding and ameliorate rheumatoid arthritis in mice. Cell Chem Biol 31: 452\u2013464.e10.","DOI":"10.1016\/j.chembiol.2023.10.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 McMillan D, Martinez-Fleites C, Porter J, Fox D, 3rd, Davis R, et al. (2021) Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF. Nat Commun 12: 582.","DOI":"10.1038\/s41467-020-20828-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Zeng J, Loi GWZ, Saipuljumri EN, Romero Dur\u00e1n MA, Silva-Garc\u00eda O, et al. (2024) Peptide-based allosteric inhibitor targets TNFR1 conformationally active region and disables receptor-ligand signaling complex. Proc Natl Acad Sci U S A 121: e2308132121.","DOI":"10.1073\/pnas.2308132121"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Torrey H, K\u00fchtreiber WM, Okubo Y, Tran L, Case K, et al. (2020) A novel TNFR2 agonist antibody expands highly potent regulatory T cells. Sci Signal 13: eaba9600.","DOI":"10.1126\/scisignal.aba9600"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Ronin E, Pouchy C, Khosravi M, Hilaire M, Gr\u00e9goire S, et al. (2021) Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2-expressing Treg cells. Proc Natl Acad Sci U S A 118: e2014043118.","DOI":"10.1073\/pnas.2014043118"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Sharifkhodaei Z, Liu CY, Girish N, Huang Y, Punit S, et al. (2023) Colitis-induced upregulation of tumor necrosis factor receptor-2 (TNFR2) terminates epithelial regenerative signaling to restore homeostasis. iScience 26: 107829.","DOI":"10.1016\/j.isci.2023.107829"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Watson S, Cabrera-Silva RI, Parkos CA, Nusrat A, Quiros M (2024) Interferon-gamma signaling drives epithelial TNF-alpha receptor-2 expression during colonic tissue repair. FASEB J 38: e70001.","DOI":"10.1096\/fj.202401695"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Raffaele S, Thougaard E, Laursen CCH, Gao H, Andersen KM, et al. (2024) Microglial TNFR2 signaling regulates the inflammatory response after CNS injury in a sex-specific fashion. Brain Behav Immun 116: 269\u2013285.","DOI":"10.1016\/j.bbi.2023.12.025"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Pegoretti V, Boerema A, Kats K, Dafauce Garcia JM, Fischer R, et al. (2025) Single intracerebroventricular TNFR2 agonist injection impacts remyelination in the cuprizone model. J Mol Med (Berl) 103: 795\u2013807.","DOI":"10.1007\/s00109-025-02549-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Liao P, Chen Z, Gao Y, Yang Y, Chen Y, et al. (2025) A novel TNFR2 agonist peptide for the expansion of CD4+Foxp3+ regulatory T cells. Front Immunol 16: 1696587.","DOI":"10.3389\/fimmu.2025.1696587"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, et al. (2012) Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23: 507\u2013515.","DOI":"10.1681\/ASN.2011060627"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Murakoshi M, Kamei N, Suzuki Y, Kubota M, Sanuki M, et al. (2023) Circulating tumor necrosis factor-related biomarkers predict kidney function decline in Japanese patients with diabetes: an observational cohort study. Diabetes Res Clin Pract 206: 111017.","DOI":"10.1016\/j.diabres.2023.111017"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, et al. (2012) Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23: 516\u2013524.","DOI":"10.1681\/ASN.2011060628"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, et al. (2015) Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 87: 812\u2013819.","DOI":"10.1038\/ki.2014.330"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Pavkov ME, Weil EJ, Fufaa GD, Nelson RG, Lemley KV, et al. (2016) Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int 89: 226\u2013234.","DOI":"10.1038\/ki.2015.278"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Barr ELM, Barzi F, Hughes JT, Jerums G, Hoy WE, et al. (2018) High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in Indigenous Australians with diabetes: the eGFR follow-up study. Diabetes Care 41: 739\u2013747.","DOI":"10.2337\/dc17-1919"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Chang LH, Hwu CM, Chu CH, Lin YC, Huang CC, et al. (2021) The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus. J Endocrinol Invest 44: 2609\u20132619.","DOI":"10.1007\/s40618-021-01568-7"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Chang LH, Chang TT, Chu CH, Huang CC, Lin LY (2024) Soluble tumor necrosis factor receptor type 1 is an alternative marker of urinary albumin-creatinine ratio and estimated glomerular filtration rate for predicting the decline of renal function in subjects with type 2 diabetes mellitus. Clin Chim Acta 558: 117880.","DOI":"10.1016\/j.cca.2024.117880"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Wu TH, Chang LH, Chu CH, Hwu CM, Chen HS, et al. (2022) Soluble tumor necrosis factor receptor 2 is associated with progressive diabetic kidney disease in patients with type 2 diabetes mellitus. PLoS One 17: e0266854.","DOI":"10.1371\/journal.pone.0266854"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Ihara K, Skupien J, Krolewski B, Md Dom ZI, O\u2019Neil K, et al. (2021) A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders. Kidney Int 99: 725\u2013736.","DOI":"10.1016\/j.kint.2020.07.007"},{"key":"38","doi-asserted-by":"crossref","first-page":"e178373","DOI":"10.1172\/jci.insight.178373","volume":"9","author":"K Ihara","year":"2024","unstructured":"38 Ihara K, Satake E, Wilson PC, Krolewski B, Kobayashi H, et al. (2024) Circulating proteins linked to apoptosis processes and fast development of end-stage kidney disease in diabetes. JCI Insight 9: e178373.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Chang LH, Chu CH, Huang CC, Lin LY (2023) Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus. Ther Adv Endocrinol Metab 14: 20420188231207345.","DOI":"10.1177\/20420188231207345"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Carlsson AC, \u00d6stgren CJ, Nystrom FH, L\u00e4nne T, Jennersj\u00f6 P, et al. (2016) Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes. Cardiovasc Diabetol 15: 40.","DOI":"10.1186\/s12933-016-0359-8"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Shai I, Schulze MB, Manson JE, Rexrode KM, Stampfer MJ, et al. (2005) A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care 28: 1376\u20131382.","DOI":"10.2337\/diacare.28.6.1376"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42 Saulnier PJ, Gand E, Ragot S, Ducrocq G, Halimi JM, et al. (2014) Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort. Diabetes Care 37: 1425\u20131431.","DOI":"10.2337\/dc13-2580"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Fern\u00e1ndez-Ju\u00e1rez G, Villacorta Perez J, Lu\u00f1o Fern\u00e1ndez JL, Martinez-Martinez E, Cachofeiro V, et al. (2017) High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy. Nephrology (Carlton) 22: 354\u2013360.","DOI":"10.1111\/nep.12781"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Nativel M, Schneider F, Saulnier PJ, Gand E, Ragot S, et al. (2018) Prognostic values of inflammatory and redox status biomarkers on the risk of major lower-extremity artery disease in individuals with type 2 diabetes. Diabetes Care 41: 2162\u20132169.","DOI":"10.2337\/dc18-0695"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Gohda T, Maruyama S, Kamei N, Yamaguchi S, Shibata T, et al. (2017) Circulating TNF receptors 1 and 2 predict mortality in patients with end-stage renal disease undergoing dialysis. Sci Rep 7: 43520.","DOI":"10.1038\/srep43520"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Chen TK, Estrella MM, Katz R, Sarnak MJ, Grams ME, et al. (2024) Plasma biomarkers of kidney health and mortality in diabetes and chronic kidney disease in the REGARDS study. Clin J Am Soc Nephrol 19: 1585\u20131593.","DOI":"10.2215\/CJN.0000000000000544"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Neirynck N, Glorieux G, Schepers E, Verbeke F, Vanholder R (2015) Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: a prospective cohort study. PLoS One 10: e0122073.","DOI":"10.1371\/journal.pone.0122073"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Marti CN, Khan H, Mann DL, Georgiopoulou VV, Bibbins-Domingo K, et al. (2014) Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study. Circ Heart Fail 7: 5\u201311.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000344"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Forsblom C, Moran J, Harjutsalo V, Loughman T, Wad\u00e9n J, et al. (2014) Added value of soluble tumor necrosis factor-\u03b1 receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care 37: 2334\u20132342.","DOI":"10.2337\/dc14-0225"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Moroney E, Niewczas MA, Ekinci EI, MacIsaac RJ (2026) Soluble Tumor Necrosis Factor Receptors (sTNFRs) as biomarkers for Diabetic Kidney Disease. J Diabetes Complications 40: 109204.","DOI":"10.1016\/j.jdiacomp.2025.109204"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Waijer SW, Sen T, Arnott C, Neal B, Kosterink JGW, et al. (2022) Association between TNF receptors and KIM-1 with kidney outcomes in early-stage diabetic kidney disease. Clin J Am Soc Nephrol 17: 251\u2013259.","DOI":"10.2215\/CJN.08780621"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, et al. (2018) Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int 93: 1198\u20131206.","DOI":"10.1016\/j.kint.2017.11.024"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, et al. (2017) Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int 92: 258\u2013266.","DOI":"10.1016\/j.kint.2017.02.010"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Lee JE, Gohda T, Walker WH, Skupien J, Smiles AM, et al. (2013) Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS One 8: e58007.","DOI":"10.1371\/journal.pone.0058007"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Carlsson AC, Jansson JH, S\u00f6derberg S, Ruge T, Larsson A, et al. (2018) Levels of soluble tumor necrosis factor receptor 1 and 2, gender, and risk of myocardial infarction in Northern Sweden. Atherosclerosis 272: 41\u201346.","DOI":"10.1016\/j.atherosclerosis.2018.03.020"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Svensson EH, S\u00f6derholm M, Abul-Kasim K, Engstr\u00f6m G (2017) Tumor Necrosis Factor Receptor 1 and 2 Are Associated With Risk of Intracerebral Hemorrhage. Stroke 48: 2710\u20132715.","DOI":"10.1161\/STROKEAHA.117.017849"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Park M, Maristany D, Huang D, Shlipak MG, Whooley M (2017) Associations of tumor necrosis factor alpha receptor type 1 with kidney function decline, cardiovascular events, and mortality risk in persons with coronary artery disease: Data from the Heart and Soul Study. Atherosclerosis 263: 68\u201373.","DOI":"10.1016\/j.atherosclerosis.2017.05.021"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Kuo JZ, Guo X, Klein R, Klein BE, Cui J, et al. (2012) Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics. Ophthalmology 119: 1041\u20131046.","DOI":"10.1016\/j.ophtha.2011.10.040"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Sharma S, Purohit S, Sharma A, Hopkins D, Steed L, et al. (2015) Elevated serum levels of soluble TNF receptors and adhesion molecules are associated with diabetic retinopathy in patients with type-1 diabetes. Mediators Inflamm 2015: 279393.","DOI":"10.1155\/2015\/279393"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Muni RH, Kohly RP, Lee EQ, Manson JE, Semba RD, et al. (2013) Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmol 131: 514\u2013521.","DOI":"10.1001\/jamaophthalmol.2013.2299"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Purohit S, Tran PMH, Tran LKH, Satter KB, He M, et al. (2021) Serum levels of inflammatory proteins are associated with peripheral neuropathy in a cross-sectional type-1 diabetes cohort. Front Immunol 12: 654233.","DOI":"10.3389\/fimmu.2021.654233"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Kulseng B, Vatten L, Espevik T (1999) Soluble tumor necrosis factor receptors in sera from patients with insulin-dependent diabetes mellitus: relations to duration and complications of disease. Acta Diabetol 36: 99\u2013105.","DOI":"10.1007\/s005920050152"},{"key":"63","doi-asserted-by":"publisher","unstructured":"63 Gao X, Belmadani S, Picchi A, Xu X, Potter BJ, et al. (2007) Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 115: 245\u2013254.","DOI":"10.1161\/CIRCULATIONAHA.106.650671"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, et al. (2006) Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 99: 69\u201377.","DOI":"10.1161\/01.RES.0000229685.37402.80"},{"key":"65","unstructured":"65 Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, et al. (2009) TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis 15: 1418\u20131428."},{"key":"66","doi-asserted-by":"publisher","unstructured":"66 Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, et al. (2005) Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects <i>via<\/i> inhibition of Akt substrate 160 phosphorylation. Diabetes 54: 2939\u20132945.","DOI":"10.2337\/diabetes.54.10.2939"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, et al. (2008) Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 172: 1411\u20131418.","DOI":"10.2353\/ajpath.2008.071070"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, et al. (2007) Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 102: 500\u2013507.","DOI":"10.1007\/s00395-007-0673-0"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Nishad R, Mukhi D, Kethavath S, Raviraj S, Paturi ASV, et al. (2022) Podocyte derived TNF-\u03b1 mediates monocyte differentiation and contributes to glomerular injury. FASEB J 36: e22622.","DOI":"10.1096\/fj.202200923R"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Wang X, Liu XQ, Jiang L, Huang YB, Zeng HX, et al. (2022) Paeoniflorin directly binds to TNFR1 to regulate podocyte necroptosis in diabetic kidney disease. Front Pharmacol 13: 966645.","DOI":"10.3389\/fphar.2022.966645"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Aquilano K, Ceci V, Gismondi A, De Stefano S, Iacovelli F, et al. (2019) Adipocyte metabolism is improved by TNF receptor-targeting small RNAs identified from dried nuts. Commun Biol 2: 317.","DOI":"10.1038\/s42003-019-0563-7"},{"key":"72","doi-asserted-by":"crossref","first-page":"e132306","DOI":"10.1172\/jci.insight.132306","volume":"5","author":"AD denDekker","year":"2020","unstructured":"72 denDekker AD, Davis FM, Joshi AD, Wolf SJ, Allen R, et al. (2020) TNF-\u03b1 regulates diabetic macrophage function through the histone acetyltransferase MOF. JCI Insight 5: e132306.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Li X, Wang M, Wolfsgruber M, Klatt OC, Hollmann MW, et al. (2025) Empagliflozin prevents TNF-\u03b1 induced endothelial dysfunction under flow\u2014the potential involvement of calcium and sodium-hydrogen exchanger. Eur J Pharmacol 986: 177147.","DOI":"10.1016\/j.ejphar.2024.177147"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Qiao S, Hong L, Zhu Y, Zha J, Wang A, et al. (2022) RIPK1-RIPK3 mediates myocardial fibrosis in type 2 diabetes mellitus by impairing autophagic flux of cardiac fibroblasts. Cell Death Dis 13: 147.","DOI":"10.1038\/s41419-022-04587-1"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594\u20131602.","DOI":"10.1056\/NEJM200011303432202"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Richter F, Liebig T, Guenzi E, Herrmann A, Scheurich P, et al. (2013) Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and <i>in vitro<\/i> bioactivity. PLoS One 8: e72156.","DOI":"10.1371\/journal.pone.0072156"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Richter F, Williams SK, John K, Huber C, Vaslin C, et al. (2021) The TNFR1 antagonist Atrosimab is therapeutic in mouse models of acute and chronic inflammation. Front Immunol 12: 705485.","DOI":"10.3389\/fimmu.2021.705485"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 He X, Landman S, Bauland SC, van den Dolder J, Koenen HJ, et al. (2016) A TNFR2-agonist facilitates high purity expansion of human low purity Treg cells. PLoS One 11: e0156311.","DOI":"10.1371\/journal.pone.0156311"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, et al. (2017) Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Pharmacol Res Perspect 5: e00365.","DOI":"10.1002\/prp2.365"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Weisel K, Scott N, Berger S, Wang S, Brown K, et al. (2021) A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol 8: e000680.","DOI":"10.1136\/bmjgast-2021-000680"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098\u20131104.","DOI":"10.1056\/NEJMoa011110"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, et al. (2009) Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32: 1244\u20131249.","DOI":"10.2337\/dc09-0054"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, et al. (2020) Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med 383: 2007\u20132017.","DOI":"10.1056\/NEJMoa2006136"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, et al. (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42: 517\u2013525.","DOI":"10.1159\/000088261"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166: 902\u2013908.","DOI":"10.1001\/archinte.166.8.902"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Zettlitz KA, Lorenz V, Landauer K, M\u00fcnkel S, Herrmann A, et al. (2010) ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs 2: 639\u2013647.","DOI":"10.4161\/mabs.2.6.13583"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Richter F, Seifert O, Herrmann A, Pfizenmaier K, Kontermann RE (2019) Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc. MAbs 11: 653\u2013665.","DOI":"10.1080\/19420862.2019.1596512"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Steeland S, Puim\u00e8ge L, Vandenbroucke RE, Van Hauwermeiren F, Haustraete J, et al. (2015) Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem 290: 4022\u20134037.","DOI":"10.1074\/jbc.M114.617787"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Vunnam N, Been M, Huber E, Paulson C, Szymonski S, et al. (2023) Discovery of a non-competitive TNFR1 antagonist affibody with picomolar monovalent potency that does not affect TNFR2 function. Mol Pharm 20: 1884\u20131897.","DOI":"10.1021\/acs.molpharmaceut.2c00385"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Vugler A, O\u2019Connell J, Nguyen MA, Weitz D, Leeuw T, et al. (2022) An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis. Front Pharmacol 13: 1037983.","DOI":"10.3389\/fphar.2022.1037983"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Davuluri KS, Singh AK, Yadav VK, Singh AV, Singh SV, et al. (2023) Dominant negative biologics normalise the tumour necrosis factor (TNF-\u03b1) induced angiogenesis which exploits the Mycobacterium tuberculosis dissemination. BMC Immunol 24: 49.","DOI":"10.1186\/s12865-023-00576-x"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Inoue M, Yamashita K, Tsuji Y, Miki M, Amano S, et al. (2021) Characterization of a TNFR2-selective agonistic TNF-\u03b1 mutant and its derivatives as an optimal regulatory T cell expander. J Immunol 206: 1740\u20131751.","DOI":"10.4049\/jimmunol.2000871"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Pegoretti V, Bauer J, Fischer R, Paro I, Douwenga W, et al. (2023) Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS. J Neuroinflammation 20: 106.","DOI":"10.1186\/s12974-023-02785-y"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/8\/73_EJ26-0050\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:29:09Z","timestamp":1786159749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/8\/73_EJ26-0050\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej26-0050","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ26-0050"}}